Helix to develop insulin skin patch for diabetics :
This article was originally published in Clinica
Executive Summary
Canada's Helix BioPharma is hoping to develop an insulin-delivering skin patch following success with the product in preclinical trials. Animal studies have shown that its Biphasix skin patch was able to deliver insulin in sustained quantities. Blood glucose levels were significantly reduced and remained reduced for more than 30 hours in diabetic rats treated with porcine insulin using the patch, said Helix of Aurora, Ontario. The company plans to develop human insulin formulations on a patch to reduce the need for injections.